ISSN: 2363-8907

Journal Home

Journal Guideline

Drug Metabolism and Personalized Therapy Q2 Unclaimed

Walter de Gruyter GmbH Germany

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Drug Metabolism and Personalized Therapy is a journal indexed in SJR in Pharmacology (medical) and Pharmacology, Toxicology and Pharmaceutics (miscellaneous) with an H index of 40. It has an SJR impact factor of 0,271 and it has a best quartile of Q2. It has an SJR impact factor of 0,271.

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q2) Pharmacology (medical) (Q3)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

Drug Metabolism and Personalized Therapy

0,271

SJR Impact factor

40

H Index

29

Total Docs (Last Year)

136

Total Docs (3 years)

1280

Total Refs

135

Total Cites (3 years)

127

Citable Docs (3 years)

1.03

Cites/Doc (2 years)

44.14

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

AIDS Research and Therapy Q2
Drug Safety - Case Reports Q2
Expert Review of Anticancer Therapy Q2
Trials Q2
American Journal of Cardiovascular Drugs Q2

Compare this journals

Aims and Scope

Best articles by citations

Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration

Metabolic phenotype prediction from genotyping data: a bottleneck for the implementation of pharmacogenetics in drug development and clinical practice

Assessment of CYP2D6 re-activation after inhibitory effect of MDMA using tramadol as a probe

Assessment of cytochrome P450 inhibition and induction potential of lupeol and betulin in rat liver microsomes

Evaluation of genotype-guided acenocoumarol dosing algorithms in Russian patients

Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects

Investigating the impact of missense mutations in hCES1 by in silico structure-based approaches

Clinical prospects of IGF-signaling system components study in ovarian cancer patients

Interethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: a report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics)

The D543N polymorphism of the SLC11A1/NRAMP1 gene is associated with treatment failure in male patients with pulmonary tuberculosis

Gene-gene interaction of ¬µ-opioid receptor and GluR5 kainate receptor subunit is associated with smoking behavior in a Greek population: presence of a dose allele effect

Correlation between plasma concentrations of tramadol and its metabolites and the incidence of seizure in tramadol-intoxicated patients

SHOW MORE ARTICLES

Altered pharmacokinetics and pharmacodynamics of repaglinide by ritonavir in rats with healthy, diabetic and impaired hepatic function

Altered pharmacokinetics of rosiglitazone in a mouse model of non-alcoholic fatty liver disease

Association of ABCB1, ABCC5 and xanthine oxidase genetic polymorphisms with methotrexate adverse reactions in Mexican pediatric patients with ALL

No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia

Predictive biomarkers candidates for patients with metastatic colorectal cancer treated with bevacizumab-containing regimen

Exploring the role of defective fibronectin matrix assembly in the VHL-associated CNS hemangioblastoma

The impact of CYP4F2, ABCB1, and GGCX polymorphisms on bleeding episodes associated with acenocoumarol in Russian patients with atrial fibrillation

Pharmacogenetic approach to losartan in Marfan patients: a starting point to improve dosing regimen?

Need for pharmacogenetic studies on the prevalence of MTHFR mutations in Puerto Ricans and Hispanics

Chloral hydrate, through biotransformation to dichloroacetate, inhibits maleylacetoacetate isomerase and tyrosine catabolism in humans

Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy

Application of the extended clearance concept classification system (ECCCS) to predict the victim drug-drug interaction potential of statins